{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:12:23Z","timestamp":1790655143199,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00109-020-01927-6","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T13:30:42Z","timestamp":1591191042000},"page":"789-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Novel therapeutic approaches for treatment of COVID-19"],"prefix":"10.1007","volume":"98","author":[{"given":"Nikoo","family":"Hossein-khannazer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahare","family":"Shokoohian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Shpichka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Asadzadeh","family":"Aghdaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-2435","authenticated-orcid":false,"given":"Peter","family":"Timashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Vosough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"1927_CR1","doi-asserted-by":"crossref","unstructured":"Zhang L, Liu Y (2020) Potential interventions for novel coronavirus in China: a systematic review. J Med Virol","DOI":"10.1002\/jmv.25707"},{"issue":"417","key":"1927_CR2","first-page":"2","volume":"8","author":"S Wang","year":"2020","unstructured":"Wang S et al (2020) Coronaviruses and the associated potential therapeutics for the viral infections. J Infect Dis Ther 8(417):2","journal-title":"J Infect Dis Ther"},{"issue":"2","key":"1927_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/pathogens9020148","volume":"9","author":"B Shanmugaraj","year":"2020","unstructured":"Shanmugaraj B, Malla A, Phoolcharoen W (2020) Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development. Pathogens 9(2):148","journal-title":"Pathogens"},{"issue":"4","key":"1927_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J (2020) Coronavirus infections and immune responses. J Med Virol 92(4):424\u2013432","journal-title":"J Med Virol"},{"key":"1927_CR5","doi-asserted-by":"crossref","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering","DOI":"10.1016\/j.eng.2020.03.007"},{"issue":"2","key":"1927_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cytogfr.2008.01.001","volume":"19","author":"V Thiel","year":"2008","unstructured":"Thiel V, Weber F (2008) Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev 19(2):121\u2013132","journal-title":"Cytokine Growth Factor Rev"},{"key":"1927_CR7","doi-asserted-by":"crossref","unstructured":"Wang D et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China. Jama","DOI":"10.1001\/jama.2020.1585"},{"issue":"10224","key":"1927_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(20)30374-3","volume":"395","author":"DL Heymann","year":"2020","unstructured":"Heymann DL, Shindo N (2020) COVID-19: what is next for public health? Lancet 395(10224):542\u2013545","journal-title":"Lancet"},{"key":"1927_CR9","doi-asserted-by":"crossref","unstructured":"Yu F et al (2020) Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect","DOI":"10.1016\/j.micinf.2020.01.003"},{"key":"1927_CR10","doi-asserted-by":"crossref","unstructured":"Yan R et al (2020) Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science","DOI":"10.1126\/science.abb2762"},{"key":"1927_CR11","doi-asserted-by":"crossref","unstructured":"Zhu R-F et al Systematic review of the registered clinical trials of coronavirus diseases 2019 (COVID-19). medRxiv:2020","DOI":"10.1101\/2020.03.01.20029611"},{"issue":"1","key":"1927_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.virusres.2007.03.015","volume":"133","author":"M Frieman","year":"2008","unstructured":"Frieman M, Heise M, Baric R (2008) SARS coronavirus and innate immunity. Virus Res 133(1):101\u2013112","journal-title":"Virus Res"},{"issue":"4","key":"1927_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/mi.2015.127","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Wei Q, Nishiura K, Peng J, Wang H, Midkiff C, Alvarez X, Qin C, Lackner A, Chen Z (2016) Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol 9(4):1089\u20131101","journal-title":"Mucosal Immunol"},{"key":"1927_CR14","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","volume":"214","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol 214:108393","journal-title":"Clin Immunol"},{"issue":"1","key":"1927_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2012.26","volume":"1","author":"H-L Janice Oh","year":"2012","unstructured":"Janice Oh H-L, Ken-En Gan S, Bertoletti A, Tan YJ (2012) Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect 1(1):1\u20136","journal-title":"Emerg Microbes Infect"},{"issue":"17","key":"1927_CR16","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","volume":"34","author":"O-W Ng","year":"2016","unstructured":"Ng O-W, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, Tan YJ (2016) Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine 34(17):2008\u20132014","journal-title":"Vaccine"},{"issue":"2","key":"1927_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4049\/jimmunol.1601542","volume":"198","author":"WJ Liu","year":"2017","unstructured":"Liu WJ, Lan J, Liu K, Deng Y, Yao Y, Wu S, Chen H, Bao L, Zhang H, Zhao M, Wang Q, Han L, Chai Y, Qi J, Zhao J, Meng S, Qin C, Gao GF, Tan W (2017) Protective T cell responses featured by concordant recognition of Middle East respiratory syndrome coronavirus\u2013derived CD8+ T cell epitopes and host MHC. J Immunol 198(2):873\u2013882","journal-title":"J Immunol"},{"key":"1927_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.antiviral.2016.11.006","volume":"137","author":"WJ Liu","year":"2017","unstructured":"Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF (2017) T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antivir Res 137:82\u201392","journal-title":"Antivir Res"},{"key":"1927_CR19","doi-asserted-by":"crossref","unstructured":"Diao B et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv","DOI":"10.1101\/2020.02.18.20024364"},{"key":"1927_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ (2019) CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 37:457\u2013495","journal-title":"Annu Rev Immunol"},{"issue":"10223","key":"1927_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497\u2013506","journal-title":"Lancet"},{"key":"1927_CR22","doi-asserted-by":"crossref","unstructured":"Zheng M et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol:1\u20133","DOI":"10.1038\/s41423-020-0402-2"},{"key":"1927_CR23","doi-asserted-by":"crossref","unstructured":"Zhou Y et al (2020) Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv","DOI":"10.1101\/2020.02.12.945576"},{"key":"1927_CR24","doi-asserted-by":"crossref","unstructured":"Vetter P, Eckerle I, Kaiser L (2020) Covid-19: a puzzle with many missing pieces. British Medical Journal Publishing Group","DOI":"10.1136\/bmj.m627"},{"key":"1927_CR25","doi-asserted-by":"crossref","unstructured":"Casadevall A, Pirofski L-a (2020) The convalescent sera option for containing COVID-19. J Clin Invest 130(4)","DOI":"10.1172\/JCI138003"},{"key":"1927_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijid.2015.10.009","volume":"41","author":"X-X Wu","year":"2015","unstructured":"Wu X-X, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ (2015) Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis 41:3\u20135","journal-title":"Int J Infect Dis"},{"issue":"4","key":"1927_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S1473-3099(18)30002-1","volume":"18","author":"JH Beigel","year":"2018","unstructured":"Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, Davey RT Jr (2018) Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 18(4):410\u2013418","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1927_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1490-9","volume":"4","author":"Y Arabi","year":"2015","unstructured":"Arabi Y et al (2015) Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 4(1):1\u20138","journal-title":"Springerplus"},{"key":"1927_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2017.03.025","volume":"143","author":"N van Doremalen","year":"2017","unstructured":"van Doremalen N, Falzarano D, Ying T, de Wit E, Bushmaker T, Feldmann F, Okumura A, Wang Y, Scott DP, Hanley PW, Feldmann H, Dimitrov DS, Munster VJ (2017) Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antivir Res 143:30\u201337","journal-title":"Antivir Res"},{"issue":"10","key":"1927_CR30","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.7150\/ijbs.45123","volume":"16","author":"G Zhou","year":"2020","unstructured":"Zhou G, Zhao Q (2020) Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci 16(10):1718\u20131723","journal-title":"Int J Biol Sci"},{"issue":"17","key":"1927_CR31","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci 117(17):9490\u20139496","journal-title":"Proc Natl Acad Sci"},{"key":"1927_CR32","doi-asserted-by":"crossref","unstructured":"Tiberghien P, Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y (2020) Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sang","DOI":"10.1111\/vox.12926"},{"issue":"2","key":"1927_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","volume":"451","author":"S-F Wang","year":"2014","unstructured":"Wang S-F, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YMA, Huang JC (2014) Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 451(2):208\u2013214","journal-title":"Biochem Biophys Res Commun"},{"key":"1927_CR34","doi-asserted-by":"crossref","unstructured":"Zand M and J Wang Potential mechanisms of age related severity of COVID-19 infection: implications for vaccine development and convalescent serum therapy. 2020.","DOI":"10.31219\/osf.io\/f3pze"},{"issue":"14","key":"1927_CR35","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","volume":"79","author":"AB Bakker","year":"2005","unstructured":"Bakker AB et al (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79(14):9062\u20139068","journal-title":"J Virol"},{"issue":"509","key":"1927_CR36","doi-asserted-by":"publisher","first-page":"eaax3447","DOI":"10.1126\/scitranslmed.aax3447","volume":"11","author":"MC Sneller","year":"2019","unstructured":"Sneller MC et al (2019) An open-label phase 1 clinical trial of the anti-\u03b14\u03b27 monoclonal antibody vedolizumab in HIV-infected individuals. Sci Transl Med 11(509):eaax3447","journal-title":"Sci Transl Med"},{"issue":"4","key":"1927_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11684-017-0596-6","volume":"11","author":"Y Jin","year":"2017","unstructured":"Jin Y, Lei C, Hu D, Dimitrov DS, Ying T (2017) Human monoclonal antibodies as candidate therapeutics against emerging viruses. Front Med 11(4):462\u2013470","journal-title":"Front Med"},{"issue":"3","key":"1927_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jiph.2016.04.003","volume":"9","author":"D Corti","year":"2016","unstructured":"Corti D, Passini N, Lanzavecchia A, Zambon M (2016) Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J Infect Public Health 9(3):231\u2013235","journal-title":"J Infect Public Health"},{"issue":"29","key":"1927_CR39","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.1073\/pnas.0701000104","volume":"104","author":"Z Zhu","year":"2007","unstructured":"Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS (2007) Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci 104(29):12123\u201312128","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1927_CR40","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1073\/pnas.0307140101","volume":"101","author":"J Sui","year":"2004","unstructured":"Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico ASC, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci 101(8):2536\u20132541","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1927_CR41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm1080","volume":"10","author":"E Traggiai","year":"2004","unstructured":"Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10(8):871\u2013875","journal-title":"Nat Med"},{"issue":"33","key":"1927_CR42","doi-asserted-by":"publisher","first-page":"10473","DOI":"10.1073\/pnas.1510199112","volume":"112","author":"D Corti","year":"2015","unstructured":"Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, Fernandez-Rodriguez B, Foglierini M, Agatic G, Vanzetta F, Gopal R, Langrish CJ, Barrett NA, Sallusto F, Baric RS, Varani L, Zambon M, Perlman S, Lanzavecchia A (2015) Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci 112(33):10473\u201310478","journal-title":"Proc Natl Acad Sci"},{"issue":"326","key":"1927_CR43","doi-asserted-by":"publisher","first-page":"326ra21-326ra21","DOI":"10.1126\/scitranslmed.aaf1061","volume":"8","author":"T Luke","year":"2016","unstructured":"Luke T et al (2016) Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 8(326):326ra21-326ra21","journal-title":"Sci Transl Med"},{"key":"1927_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.virol.2016.01.004","volume":"490","author":"RF Johnson","year":"2016","unstructured":"Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA (2016) 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3\/2012. Virology 490:49\u201358","journal-title":"Virology"},{"key":"1927_CR45","doi-asserted-by":"crossref","unstructured":"Chen W-H, PJ Hotez, and ME Bottazzi Potential for developing the SARS-CoV receptor binding domain recombinant protein (RBD) as a heterologous human vaccine for SARS-CoV-2. 2020","DOI":"10.1080\/21645515.2020.1740560"},{"key":"1927_CR46","doi-asserted-by":"crossref","unstructured":"Zheng Z et al (2020) Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2. bioRxiv","DOI":"10.1101\/2020.03.06.980037"},{"issue":"10224","key":"1927_CR47","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S0140-6736(20)30305-6","volume":"395","author":"A Zumla","year":"2020","unstructured":"Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M (2020) Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 395(10224):e35\u2013e36","journal-title":"Lancet"},{"key":"1927_CR48","unstructured":"Xu X et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab, in China. Xiv:20200300026"},{"issue":"3","key":"1927_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.6026\/97320630016219","volume":"16","author":"F Chiappelli","year":"2020","unstructured":"Chiappelli F, Khakshooy A, Greenberg G (2020) CoViD-19 Immunopathology & Immunotherapy. Bioinformation 16(3):219\u2013222","journal-title":"Bioinformation"},{"issue":"10223","key":"1927_CR50","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395(10223):e30\u2013e31","journal-title":"Lancet"},{"key":"1927_CR51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P (2020) COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 20:400\u2013402","journal-title":"Lancet Infect Dis"},{"key":"1927_CR52","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","volume":"221","author":"F Wang","year":"2020","unstructured":"Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y (2020) Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 221:1762\u20131769","journal-title":"J Infect Dis"},{"key":"1927_CR53","doi-asserted-by":"crossref","unstructured":"Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, Zhou W, Chen D, Zhou L, Wang M, Wu M, Huang Q, Xu H, Zeng W, Guo L (2020) Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect","DOI":"10.1016\/j.jinf.2020.03.054"},{"issue":"2","key":"1927_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1084\/jem.20150712","volume":"213","author":"S Madera","year":"2016","unstructured":"Madera S, Rapp M, Firth MA, Beilke JN, Lanier LL, Sun JC (2016) Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. J Exp Med 213(2):225\u2013233","journal-title":"J Exp Med"},{"key":"1927_CR55","doi-asserted-by":"crossref","unstructured":"Shi Y et al (2020) Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. medRxiv","DOI":"10.1101\/2020.03.12.20034736"},{"key":"1927_CR56","doi-asserted-by":"crossref","unstructured":"Wan S et al (2020) Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). Medrxiv","DOI":"10.1101\/2020.02.10.20021832"},{"key":"1927_CR57","doi-asserted-by":"crossref","unstructured":"Weiskopf D et al (2020) Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. medRxiv","DOI":"10.1126\/sciimmunol.abd2071"},{"key":"1927_CR58","unstructured":"Liang B et al Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells"},{"key":"1927_CR59","doi-asserted-by":"crossref","unstructured":"Hashemi SM et al (2019) Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice. Inflammopharmacology:1\u201317","DOI":"10.1007\/s10787-019-00661-x"},{"key":"1927_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lfs.2018.11.040","volume":"216","author":"N Hossein-Khannazer","year":"2019","unstructured":"Hossein-Khannazer N et al (2019) Study of the immunomodulatory effects of osteogenic differentiated human dental pulp stem cells. Life Sci 216:111\u2013118","journal-title":"Life Sci"},{"issue":"1","key":"1927_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13287-016-0395-z","volume":"7","author":"Y Li","year":"2016","unstructured":"Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, Lu W, Han XD (2016) Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther 7(1):159","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1927_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-018-0774-8","volume":"9","author":"M Khatri","year":"2018","unstructured":"Khatri M, Richardson LA, Meulia T (2018) Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther 9(1):1\u201313","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"1927_CR63","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/cells9040924","volume":"9","author":"E Bari","year":"2020","unstructured":"Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG (2020) Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. Cells 9(4):924","journal-title":"Cells"},{"key":"1927_CR64","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.medidd.2020.100019","volume":"5","author":"SM Metcalfe","year":"2020","unstructured":"Metcalfe SM (2020) Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 5:100019","journal-title":"Med Drug Discov"},{"issue":"2","key":"1927_CR65","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC (2020) Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11(2):216\u2013228","journal-title":"Aging Dis"},{"issue":"2","key":"1927_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.14336\/AD.2020.0301","volume":"11","author":"AK Shetty","year":"2020","unstructured":"Shetty AK (2020) Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis 11(2):462\u2013464","journal-title":"Aging Dis"},{"issue":"1","key":"1927_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12865-014-0041-4","volume":"15","author":"RF Foronjy","year":"2014","unstructured":"Foronjy RF, Dabo AJ, Cummins N, Geraghty P (2014) Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol 15(1):41","journal-title":"BMC Immunol"},{"issue":"3","key":"1927_CR68","first-page":"L548","volume":"313","author":"KE Traber","year":"2017","unstructured":"Traber KE et al (2017) Myeloid-epithelial cross talk coordinates synthesis of the tissue-protective cytokine leukemia inhibitory factor during pneumonia. Am J Phys Lung Cell Mol Phys 313(3):L548\u2013L558","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"1927_CR69","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2147\/COPD.S196658","volume":"14","author":"J Poon","year":"2019","unstructured":"Poon J, Campos M, Foronjy RF, Nath S, Gupta G, Railwah C, Dabo AJ, Baumlin N, Salathe M, Geraghty P (2019) Cigarette smoke exposure reduces leukemia inhibitory factor levels during respiratory syncytial viral infection. Int J Chronic Obstruct Pulmonary Dis 14:1305\u20131315","journal-title":"Int J Chronic Obstruct Pulmonary Dis"},{"issue":"Godi\u0161te 2015","key":"1927_CR70","first-page":"2","volume":"2","author":"SM Metcalfe","year":"2015","unstructured":"Metcalfe SM et al (2015) Multiple sclerosis and the LIF\/IL-6 axis: use of nanotechnology to harness the tolerogenic and reparative properties of LIF. Nanobiomedicine 2(Godi\u0161te 2015):2\u20135","journal-title":"Nanobiomedicine"},{"issue":"1","key":"1927_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0560-5","volume":"18","author":"L Wang","year":"2020","unstructured":"Wang L et al (2020) Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury. J Nanobiotechnol 18(1):1\u201316","journal-title":"J Nanobiotechnol"},{"key":"1927_CR72","doi-asserted-by":"crossref","unstructured":"Tolouian R et al (2020) COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. J Renal Injury Prevent 9(2)","DOI":"10.34172\/jrip.2020.19"},{"key":"1927_CR73","doi-asserted-by":"crossref","unstructured":"Cheng H, Wang Y, Wang GQ (2020) Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol","DOI":"10.1002\/jmv.25785"},{"key":"1927_CR74","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, M\u00fcller MA, Drosten C, P\u00f6hlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271\u2013280.e8","journal-title":"Cell"},{"key":"1927_CR75","doi-asserted-by":"crossref","unstructured":"Ju B et al (2020) Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv","DOI":"10.1101\/2020.03.21.990770"},{"issue":"7047","key":"1927_CR76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112\u2013116","journal-title":"Nature"},{"key":"1927_CR77","doi-asserted-by":"crossref","unstructured":"Zhang H et al (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med:1\u20135","DOI":"10.1007\/s00134-020-05985-9"},{"key":"1927_CR78","doi-asserted-by":"crossref","unstructured":"Monteil V (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. cellpress","DOI":"10.1016\/j.cell.2020.04.004"},{"key":"1927_CR79","doi-asserted-by":"crossref","unstructured":"Lukassen S et al (2020) SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches. bioRxiv","DOI":"10.1101\/2020.03.13.991455"},{"key":"1927_CR80","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 34:101615","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"1927_CR81","doi-asserted-by":"publisher","first-page":"019","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11(1):019\u201313940","journal-title":"Nat Commun"},{"key":"1927_CR82","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"K-T Choy","year":"2020","unstructured":"Choy K-T, Wong AYL, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PPH, Huang X, Peiris M, Yen HL (2020) Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir Res 178:104786","journal-title":"Antivir Res"},{"key":"1927_CR83","doi-asserted-by":"crossref","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D\u2019Arminio Monforte A, Ismail S, Kato H, Lapadula G, L\u2019Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med","DOI":"10.1056\/NEJMoa2007016"},{"issue":"10","key":"1927_CR84","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK, Washington State 2019-nCoV Case Investigation Team (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929\u2013936","journal-title":"N Engl J Med"},{"key":"1927_CR85","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, du G, du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569\u20131578","journal-title":"Lancet"},{"issue":"3","key":"1927_CR86","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijpddr.2018.10.002","volume":"8","author":"AC Aguiar","year":"2018","unstructured":"Aguiar AC et al (2018) Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 8(3):459\u2013464","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"1927_CR87","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"A Cortegiani","year":"2020","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 57:279\u2013283","journal-title":"J Crit Care"},{"issue":"69","key":"1927_CR88","first-page":"2","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2(69):2\u201369","journal-title":"Virol J"},{"issue":"3","key":"1927_CR89","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2014.12.FOCUS14748","volume":"38","author":"EB Golden","year":"2015","unstructured":"Golden EB, Cho HY, Hofman FM, Louie SG, Sch\u00f6nthal AH, Chen TC (2015) Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 38(3):E12","journal-title":"Neurosurg Focus"},{"key":"1927_CR90","doi-asserted-by":"crossref","unstructured":"Chen Z et al (2020) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv","DOI":"10.1101\/2020.03.22.20040758"},{"key":"1927_CR91","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honor\u00e9 S, Colson P, Chabri\u00e8re E, la Scola B, Rolain JM, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents:105949","DOI":"10.1101\/2020.03.16.20037135"},{"issue":"4","key":"1927_CR92","doi-asserted-by":"publisher","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mour\u00e3o MPG, Brito-Sousa JD, Ba\u00eda-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO Jr, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ, Albuquerque BC, Daniel-Ribeiro CT, Monteiro WM, Lacerda MVG, for the CloroCovid-19 Team (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3(4):e208857\u2013e208857","journal-title":"JAMA Netw Open"},{"key":"1927_CR93","doi-asserted-by":"crossref","unstructured":"Jakhar D, Kaur I (2020) Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med:1\u20131","DOI":"10.1038\/s41591-020-0853-0"},{"issue":"8","key":"1927_CR94","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","volume":"63","author":"RS Cvetkovic","year":"2003","unstructured":"Cvetkovic RS, Goa KL (2003) Lopinavir\/ritonavir: a review of its use in the management of HIV infection. Drugs 63(8):769\u2013802","journal-title":"Drugs"},{"issue":"1","key":"1927_CR95","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","volume":"19","author":"YM Arabi","year":"2018","unstructured":"Arabi YM et al (2018) Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19(1):81","journal-title":"Trials"},{"issue":"3","key":"1927_CR96","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"C Chu","year":"2004","unstructured":"Chu C, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY, HKU\/UCH SARS Study Group (2004) Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3):252\u2013256","journal-title":"Thorax"},{"key":"1927_CR97","doi-asserted-by":"crossref","unstructured":"Lim J et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6)","DOI":"10.3346\/jkms.2020.35.e79"},{"key":"1927_CR98","doi-asserted-by":"crossref","unstructured":"Wu C et al (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B","DOI":"10.1016\/j.apsb.2020.02.008"},{"key":"1927_CR99","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","volume":"153","author":"L Delang","year":"2018","unstructured":"Delang L, Abdelnabi R, Neyts J (2018) Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res 153:85\u201394","journal-title":"Antivir Res"},{"issue":"7","key":"1927_CR100","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Series B 93(7):449\u2013463","journal-title":"Proc Jpn Acad Series B"},{"issue":"1","key":"1927_CR101","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14(1):58\u201360","journal-title":"Drug Discov Ther"},{"issue":"6","key":"1927_CR102","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nri.2016.43","volume":"16","author":"HS Goodridge","year":"2016","unstructured":"Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, Pollard AJ, van Crevel R, Wilson CB (2016) Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol 16(6):392\u2013400","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1927_CR103","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","volume":"23","author":"RJ Arts","year":"2018","unstructured":"Arts RJ et al (2018) BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23(1):89\u2013100. e5","journal-title":"Cell Host Microbe"},{"key":"1927_CR104","doi-asserted-by":"crossref","unstructured":"Miller A et al (2020) Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv","DOI":"10.1101\/2020.03.24.20042937"},{"key":"1927_CR105","doi-asserted-by":"crossref","unstructured":"Dayal D, Gupta S (2020) Connecting BCG vaccination and COVID-19: additional data. medRxiv","DOI":"10.1101\/2020.04.07.20053272"},{"key":"1927_CR106","unstructured":"Organization WH Bacille Calmette-Gu\u00e9rin (BCG) vaccination and COVID-19: scientific brief, 12 April 2020. 2020, World Health Organization"},{"issue":"4","key":"1927_CR107","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1097\/01.CCM.0000057900.19201.55","volume":"31","author":"BT Thompson","year":"2003","unstructured":"Thompson BT (2003) Glucocorticoids and acute lung injury. Crit Care Med 31(4):S253\u2013S257","journal-title":"Crit Care Med"},{"issue":"16","key":"1927_CR108","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs. N Engl J Med 353(16):1711\u20131723","journal-title":"N Engl J Med"},{"key":"1927_CR109","doi-asserted-by":"crossref","unstructured":"Yang X et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med","DOI":"10.1016\/S2213-2600(20)30079-5"},{"key":"1927_CR110","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","volume":"39","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 39:405\u2013407","journal-title":"J Heart Lung Transplant"},{"key":"1927_CR111","doi-asserted-by":"crossref","unstructured":"Wang Y et al (2020) Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv","DOI":"10.1101\/2020.03.06.20032342"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-020-01927-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:08:54Z","timestamp":1666771734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-020-01927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1927"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-01927-6","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}